

DIVISIONS OF

Benign + Malignant Hematology
Solid Tumor Oncology

JORGE GARCIA, MD, FACP » Interim Division Chief, Benign + Malignant Hematology; Division Chief, Solid Tumor Oncology



Our three programs — Benign Hematology, Malignant Hematology/Transplant, and Solid Tumor Oncology continue to be vibrant academically and clinically.

Now more than ever, bringing our state-of-the-art and compassionate care to the regional practices has become of paramount importance. Patients are anxious to have access to sophisticated clinical research opportunities closer to their home. Although operationally challenging, that in itself has become a top priority for our cancer services.

We also had a very successful recruitment year and we expanded our faculty by 14. We recently recruited our new division chief for Hematology, an internationally known BMT expert. We expect that this recruitment will allow us to expand our clinical and academic presence in the BMT field and that our immuno-oncology and cellular therapy programs will become the cornerstone of our Malignant Hematology program. In the cellular immunotherapy space, we have some major publications reflecting the work of our translational faculty working on CAR-T development. We are poised to expand the CAR-T program to solid tumors and pilot research programs are underway.

Our patient care remains the foundation of who we are, and our entire faculty has excelled in their efforts. A reflection of this are our high patient satisfaction scores. Our teaching and education involvement is unparalleled and our faculty engagement to train the next generation of physicians is evident by the positive evaluations we received. Operationally, we continue to identify ways to improve our daily practices — all aimed to maximize patient care during their cancer journey. This certainly will have a positive impact on physician experience as well.

Undeniably, our research productivity was compromised by COVID, causing a detrimental impact on our research work force. Despite these operational challenges, our programmatic research (clinical and translational) continues to develop and expand. We predict that in addition to restructuring our CTU, better research portfolio management by our disease team leaders could enhance our research productivity for years to come. Perhaps a good reflection of our commitment to academic research and oncology excellence is our publication record. The last twelve months have been incredibly successful with many of our faculty receiving new grants, renewal of our GI SPORE, new clinical and translational research opportunities, and over 50 new manuscripts published at major academic journals.

The future of our divisions could not be brighter and will require hard work, perseverance, collaborative research, and major operational support. Lastly, our entire faculty will need their entrepreneurial skills at hand to navigate the operational and business complexities of today's health care.